LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine

Cephalalgia

Volumn 24, Issue 7, 2004, Pages 596-602

  Sang, C N ^a   Ramadan, N M ^b,c,d   Wallihan, R G ^b   Chappell, A S ^b   Freitag, F G ^e   Smith, T R ^f   Silberstein, S D ^g   Johnson, K W ^b   Phebus, L A ^b   Bleakman, D ^b   Ornstein, P L ^b   Arnold, B ^b   Tepper, S J ^h,i   Vandenhende, F ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c INDIANA UNIVERSITY   (United States)

^d ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^e DIAMOND HEADACHE CLINIC   (United States)

^f Mercy Heath Research   (United States)

^g JEFFERSON HEADACHE CENTER   (United States)

^h NEW ENGLAND CENTER FOR HEADACHE   (United States)

ⁱ YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Glutamate receptors; LY293558; Migraine; Randomized controlled trial

Indexed keywords

ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; GLUTAMATE RECEPTOR 5; GLUTAMATE RECEPTOR ANTAGONIST; KAINIC ACID RECEPTOR ANTAGONIST; PLACEBO; SUMATRIPTAN;

ACUTE DISEASE; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERANCE; FEMALE; HEADACHE; HEAT; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MIGRAINE; MULTICENTER STUDY; PAIN ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SEDATION; SIDE EFFECT; SKIN TINGLING; THORAX DISEASE; THROAT DISEASE; TREATMENT OUTCOME; VISUAL DISORDER;

ACUTE DISEASE; ADULT; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; ISOQUINOLINES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; RECEPTORS, AMPA; RECEPTORS, KAINIC ACID; TETRAZOLES;

EID: 2342483183     PISSN: 03331024     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2004.00723.x     Document Type: Article

References (18)

1. Fundytus ME. Glutamate receptors and nociception: implications for the drug treatment of pain. CNS Drugs 2001; 15:29-58.
2. Salt TE, Hill RG. Differentiation of excitatory amino acid receptors in the rat caudal trigeminal nucleus: a microiontophoretic study. Neuropharmacology 1982; 21:385-90.
3. Sahara Y, Noro N, Iida Y, Soma K, Nakamura Y. Glutamate receptor subunits GluR5 and KA-2 are coexpressed in rat trigeminal ganglion neurons. J Neurosci 1997; 17:6611-20.
4. Johnson KW, Dieckman DK, Phebus LA, et al. GluR5 antagonists as novel migraine therapies (Abstract). Cephalalgia 2001; 21:268.
5. Eisenberg E, Vos BP, Strassman AM. The NMDA antagonist memantine blocks pain behavior in a rat model of formalin-induced facial pain. Pain 1993; 54:301-7.
6. Mitsikostas DD, Sanchez del Rio M, Waeber C, Huang Z, Cutrer FM, Moskowitz MA. Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis. Br J Pharmacol 1999; 127:623-30.
7. Storer RJ, Goadsby PJ. Trigeminovascular nociceptive transmission involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors. Neuroscience 1999; 90:1371-6.
8. Mitsikostas DD, Sanchez Del Rio M. Receptor systems mediating c-fos expression within trigeminal nucleus caudalis in animal models of migraine. Brain Res Rev 2001; 35:20-35.
9. Ferrari MD, Odink J, Bos KD, Malessy MJ, Bruyn GW. Neuroexcitatory plasma amino acids are elevated in migraine. Neurology 1990; 40:1582-6.
10. Alam Z, Coombes N, Waring RH, Williams AC, Steventon GB. Plasma levels of neuroexcitatory amino acids in patients with migraine or tension headache. J Neurol Sci 1998; 156:102-6.
11. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol 2000; 47:614-24.
12. Woolf CJ, Decosterd I. Implications of recent advances in the understanding of pain pathophysiology for the assessment of pain in patients. Pain Supplement 1999; 6:S141-S147.
13. Sang CN, Hostetter MP, Gracely RH, et al. AMPA/kainate antagonist LY293558 reduces capsaicin-evoked hyperalgesia but not pain in normal skin in humans. Anesthesiology 1998; 89:1060-7.
14. Simmons RM, Li DL, Hoo KH, Deverill M, Ornstein PL, Iyengar S. Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat. Neuropharmacology 1998; 37:25-36.
15. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. Cephalalgia 1988; 8 (Suppl 7):1-96.
16. Ma QP. Co-localization of 5-HT (1B/1D/1F) receptors and glutamate in trigeminal ganglia in rats. Neuroreport 2001; 12:1589-91.
17. Jackson DL, Hargreaves KM. Activation of excitatory amino acid receptors in bovine dental pulp evokes the release of iCGRP. J Dent Res 1999; 78:54-60.
18. Shepherd AJ. Visual contrast processing in migraine. Cephalalgia 2000; 20:865-80.